J. Mark Braughler Joins RheoGene, Inc. As Vice President Of Therapeutics 
10/19/2005 5:11:31 PM

RheoGene Inc. is pleased to announce that J. Mark Braughler, Ph.D., has joined its executive management team as Vice President of Therapeutics. Dr. Braughler will head RheoGene's Clinical Applications office and laboratory in Pittsburgh, where he will direct RheoGene's preclinical and clinical development programs and oversee RheoGene's academic and institutional research collaborations. Dr. Braughler comes to RheoGene from Paradigm Genetics, Inc. (Research Triangle Park, N.C.) where he was Vice President of Business Development -- Healthcare. Dr. Braughler joined Paradigm Genetics following its acquisition of TissueInformatics Inc. (Pittsburgh PA), where he had served as Senior Vice President of Business Development and Acting COO. During his tenure at TissueInformatics, he established and guided research and commercial programs in the development of automated pathology software as well as drug target discovery in diabetes, obesity and aging that yielded a number of novel drug targets and several products. Prior to joining TissueInformatics, Dr. Braughler was CEO and President of Argonex Inc. (Charlottesville VA) where he was instrumental in the formation of RHeoGene LLC, a joint venture between Rohm and Haas Co. and Argonex Inc. that operated between 1999 and 2002, and was the predecessor company of RheoGene Inc. Prior to joining Argonex, he held several management positions at Pharmacia & Upjohn, including Vice President of Business Development.